The genetic and pharmacological inhibition of cholesterol biosynthesis enzymes, such as 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), farnesyl-diphosphate farnesyltransferase 1 (FDFT1), farnesyl pyrophosphate synthase (FDPS), and 24-dehydrocholesterol reductase (DHCR24), have been shown to reduce cancer stem cell propagation, expression of stemness-related genes OCT4, SOX2, and NANOG, and tumorigenesis [18, 21–23]. This evidence concerns the gene SOX2 and cancer.